aTyr Pharma Announces Positive Phase 1b/2a Results for ATYR1923 in Pulmonary Sarcoidosis

aTYR PHARMA INC

ATYR1923 safe and well-tolerated with no drug-related serious adverse events in 37-patient pulmonary sarcoidosis trial.
5.0 mg/kg group achieved 58% steroid reduction from baseline and 33% of patients tapered completely off steroids.
Absolute improvement in forced vital capacity (FVC) of 3.3% at week 24 in 5.0 mg/kg group vs placebo.
Clinically meaningful improvements in dyspnea, cough, fatigue and King's Sarcoidosis scores in 5.0 mg/kg group.
Company plans FDA end-of-Phase 2 meeting and expects to initiate registrational trial in 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.